Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 89 of 89 results for pulmonary hypertension

  1. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA178

  2. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing venous thromboembolism after total hip or total knee replacement in adults.

    Technology appraisal guidance
    Published
    22 April 2009
    View recommendations

    Sections for TA170

  3. Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (IPG274)

    Evidence-based recommendations on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. This involves removing parts of the pancreas (islet cells) after the pancreas has been removed and inserting them into the liver to restart insulin production.

    Interventional procedures guidance
    Published
    24 September 2008
    View recommendations

    Sections for IPG274

  4. Hybrid procedure for interim management of hypoplastic left heart syndrome in neonates (IPG246)

    Evidence-based recommendations on hybrid procedure for interim management of hypoplastic left heart syndrome in neonates. This involves placing bands around the branches of the pulmonary artery and inserting stents to keep the ductus arteriosus open.

    Interventional procedures guidance
    Published
    12 December 2007
    View recommendations

    Sections for IPG246

  5. Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) (IPG192)

    Evidence-based recommendations on therapeutic amnioinfusion for treating oligohydramnios during pregnancy (excluding labour). This involves injecting a substance similar to amniotic fluid into the space around the baby.

    Interventional procedures guidance
    Published
    22 November 2006
    View recommendations

    Sections for IPG192

  6. Living-donor lung transplantation for end-stage lung disease (IPG170)

    Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease. This involves removing a lung from each of the two donors and replacing the recipient's lungs with the donor lungs.

    Interventional procedures guidance
    Published
    24 May 2006
    View recommendations

    Sections for IPG170

  7. Balloon dilatation of systemic to pulmonary arterial shunts in children (IPG77)

    Evidence-based recommendations on balloon dilatation of systemic to pulmonary arterial shunts in children. This involves inflating a balloon inserted into the area so blood can flow through more easily.

    Interventional procedures guidance
    Published
    28 July 2004
    View recommendations

    Sections for IPG77

  8. Cardiometabolic disease prevention and treatment guidelines

    adults: investigation and management - To be confirmed Hypertension in adults: diagnosis and management - To be confirmed

    NICE guideline
    In development

  9. Macitentant–tadalafil for treating pulmonary arterial hypertension TS ID 10517

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Treprostinil diethanolamine for treating pulmonary arterial hypertension TS ID 11772

    Awaiting development [GID-TA11123] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued [GID-TAG382]

    Technology appraisal guidance
    Discontinued

  12. Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]

    Suggested remit: To appraise the clinical and cost effectiveness of treprostinil sodium within its marketing authorisation for treating chronic thromboembolic p...

    Technology appraisal guidance
    Topic selection

  13. Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years TS ID 11805

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development [GID-TA11103] Expected publication date: TBC

    Technology appraisal guidance
    In development